

Focus on Myelodysplastic Syndromes Reviewed

Guido D'ANGELO

Laboratory of Clinical-Chemistry, Hematology and Microbiology, ASST - Gallarate Hospital, Varese - ITALY

ABSTRACT

Myelodysplastic syndromes (MDSs) are neoplastic pathologies characterized by accelerated hematopoiesis and apoptosis; this results in a paradoxical condition featured by bone marrow progenitors hypercellularity compared to the peripheral cytopenia. In this review the WHO update goal is summarized. A new MDS nomenclature has been defined so as to make the diagnostic approach towards these heterogeneous diseases more rational. Methodologically, the morphology study is still considered fundamental, both for the accurate blasts counting and the dysplastic detection of one or more of the three myeloid lines. Furthermore, specific genetic mutations have not only a diagnostic and prognostic importance, but it can also define a more adherent therapeutic condition, as well as identifying blurred categories or cytopenic asymptomatic patients who can evolve towards an overt MDS.

Keywords: Myelodysplastic syndrome, WHO, Classification, Blasts, Genetic mutation

INTRODUCTION

Myelodysplastic Syndrome(s) (MDSs) are clonal disorders characterized by intramedullary simultaneous proliferation and apoptosis of hematopoietic cells.¹ The result is an ineffective hematopoiesis that results cytopenia(s) (hemoglobin (Hb) < 100g/L, absolute neutrophil count (ANC) < 1.8x10⁹/L, platelets (PLTs) < 100x10⁹/L, according to the International Prognostic Score System (IPSS).² The values should be considered not exclusionary). Another important diagnostic requirement for MDS is the dysplasia that can be present in one or more of the three myeloid lines. It should be emphasized that the myeloid term includes all cells belonging to the granulocytic, monocytic/macrophage, erythroid, megakaryocytic and mast-cells lineages. Finally, the inevitable risk that the MDS evolves towards an acute myeloid leukemia (AML).

The purpose of this review is to provide an easy-to-use tool for diagnosing MDS. These heterogeneous pathologies, which mainly affect the elderly, can show an overlap with myeloproliferative neoplasms (MDS/MPN) in same patients, while other patients may not show overt characteristics of a pre-leukemic condition.

Rational diagnostic approach for MDS Classification

According to the WHO classification³, cytochemistry, immunophenotype, genetics and clinical features are the key methods to define the MDS as a clinically significant disease entities (Table 1). The employment of the aforementioned methods allows the classification of MDS that can be used in daily clinical practice, and can serve as common language for clinical trials and laboratory investigation.

Table 1. WHO 2008 MDS Classification³

Disease	Blood findings	Bone Marrow findings
Refractory cytopenia with unilineage dysplasia (RCUD) Refractory anemia (RA) Refractory neutropenia (RN) Refractory thrombocytopenia (RT)	Unicytopenia or bicytopenia ¹ No or rare blasts (< 1%) ²	Unilineage dysplasia ≥ 10% of the cells in one myeloid lineage < 5% blasts < 15% of ring sideroblasts
Refractory anemia with ring sideroblasts (RARS)	Anemia No blasts	≥ 15% ring sideroblasts Erythroid dysplasia only < 5% blasts
Refractory cytopenia with multilineage dysplasia (RCMD)	Cytopenia(s) No or rare blasts (< 1%) ² No Auer rods < 1x10 ⁹ /L monocytes	Dysplasia in ≥ 10% of the cells ≥ two myeloid lineages (neutrophil and/or erythroid precursors and/or megakaryocytes) < 5% blasts in marrow No Auer rods ± 15% ring sideroblasts
Refractory anemia with excess blasts-1 (RAEB-1)	Cytopenia(s) < 5% blasts ² No Auer rods < 1x10 ⁹ /L monocytes	Unilineage or multilineage dysplasia 5-9% blasts ² No Auer rods
Refractory anemia with excess blasts-2 (RAEB-2)	Cytopenia(s) 5-19% blasts ³ Auer rods ± < 1x10 ⁹ /L monocytes	Unilineage or multilineage dysplasia 5-19% blasts Auer rods ±3
Myelodysplastic syndrome- Unclassifiable (MDS-U)	Cytopenia(s) Blasts (< 1%) ²	Unequivocal dysplasia in less than 10% of cells in one or more myeloid cell lines when accompanied by a cytogenetic abnormality considered as presumptive evidence for a diagnosis of MDS < 5% blasts
MDS associated with isolated del5(q)	Anemia No or rare blasts (< 1%) Normal or increased platelet count	Normal to increased megakaryocytes with hypolobated nuclei < 5% blasts Isolated del5(q) cytogenetic abnormality No Auer rods

¹ Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U
² If marrow myeloblasts percentage is < 5% but there are 2-4% myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases with RCUD and RCMD with 1% myeloblasts in the blood should be classified as MDS-U.
³ Cases with Auer rods < 5% blasts in the blood and < 10% in the marrow should be classified as RAEB-2.

2016 WHO MDS Revised Nomenclature

In 2016, the WHO proposed a MDS updates on nomenclature, morphology, immunophenotype, cytogenetic and gene mutations.⁴

Regarding the nomenclature, the WHO 2016 MDS revised, proposed a classification based on the morphological aspects of dysplasia, as well as the accurate count of blasts, not mainly on cytopenia (Table 2).

For categorizing and evaluating the disease progression, the blasts percentage ≥ 20%, in both

peripheral blood (PB) and bone marrow (BM), remains fundamental.

Regarding Refractory cytopenia with unilineage dysplasia (RCUD), it has been established that the type of dysplasia does not always fit the cytopenic cell line. Refractory Anemia (RA), Refractory Neutropenia (RN), and Refractory Thrombocytopenia (RT) subgroups are removed and the RCUD is incorporated into a single renamed group: MDS with single lineage dysplasia (MDS-SLD).

Table 2. 2016 WHO MDS ⁴	
WHO MDS classification ³	2016 WHO revised nomenclature ⁴
Refractory cytopenia with unilineage dysplasia (RCUD) • Refractory anemia (RA) • Refractory neutropenia (RN) • Refractory thrombocytopenia (RT)	MDS with single lineage dysplasia (MDS-SLD)
RA with ring sideroblasts (RARS)	MDS with ring sideroblasts with single lineage dysplasia (MDS-RSSLD)
Refractory cytopenia with multilineage dysplasia (RCMD)	MDS with ring sideroblasts with multilineage dysplasia (MDS-RSMLD)
Refractory anemia with excess of blasts (RAEB) • Refractory anemia with excess of blasts-1 (RAEB-1) • Refractory anemia with excess of blasts-2 (RAEB-2)	MDS with excess of blasts (MDS-EB) • MDS-EB1 • MDS-EB2
MDS with isolated del(5q)	MDS with isolated del(5q)
MDS unclassifiable	MDS unclassifiable
Childhood MDS • Refractory cytopenia of childhood	Childhood MDS • Refractory cytopenia of childhood

Refractory anemia with ring sideroblasts (RARS) is reclassified as MDS with ring sideroblasts with single lineage dysplasia (MDS-RSSLD). Refractory cytopenia with multilineage dysplasia (RCMD), with the new nomenclature, is divided into two groups, MDS with ring sideroblasts with multilineage dysplasia (MDS-RSMLD) and MDS with multilineage dysplasia (MDS-MLD).

The nomenclature for refractory anemia with excess of blasts (RAEB) changes in MDS with excess of blasts (MDS-EB), as well as the RAEB-1 and RAEB-2 subgroups that are renamed MDS-excess of blasts-1 (MDS-EB-1) and MDS-excess of blasts-2 (MDS-EB-2) respectively.

The nomenclature of MDS with isolated del(5q), unclassifiable MDS and childhood MDS with the subgroup refractory cytopenia of childhood does not change.

Distinctive Morphological Feature of MDS

Dysplasia

Within the new WHO classification, 10% remains the cut-off detection of dysplastic line.

Cellular characteristics of dysplastic morphology

The features of dysplastic cellular morphology⁵ are referred to nuclear and cytoplasmic dyserythropoiesis, disgranulopoiesis in myeloid-granulocytic line, and dismegakaryocytopoiesis⁶ (Table 3).

Table 3. Cellular characteristics of dysplastic morphology	
Dyserythropoiesis nuclear	Nuclear budding, internuclear bridging, karyorhexis, multinuclearity, nuclear hyperlobation, megaloblastic changes
Dyserythropoiesis cytoplasmatic	Ring sideroblasts, vacuolization, periodic acid-Schiff positivity.
Disgranulopoiesis	Small or unusually large size, nuclear hypolobation (pseudo Pelger-Huët, pelgeroid), irregular hypersegmentation, decreased granules, agranularity, pseudo Chediak-Higashi granules, Auer rods.
Dismegakaryocytopoiesis	Micromegakaryocytes, nuclear hypolobation, multinucleation (normal megakaryocytes are uninucleate with lobulated nuclei)

Table 4. Immunophenotype assay. Main monoclonal antibodies employed for studying hematopoietic dysplastic lines

Hematopoietic line	Monoclonal antibodies
Myeloid	CD16, CD11b: neutrophilic granulocytes undergoing maturation CD13/CD16 combination: neutrophilic maturation pattern CD2, CD5, CD7, and CD19, monoclonal antibodies belonging to lymphoid lineage, can be expressed abnormally both myeloid progenitors and maturing myeloid cells
Blast Cells	CD34 Most CD34+ blast cells are committed towards the myeloid lineage (CD38+, HLA-DR+, CD13+, CD33+)
Monocytic	CD56, HLA-DR, CD36, CD33, CD15, CD14, CD13, and CD11b
Erythroid	Glycophorin A (Gly A), CD71 Between the two monoclonal antibodies, the Gly A does not allow the detection of erythroid precursors more immature
Megakaryocytic and Platelets	CD61, CD41

In absence of genetic abnormalities, the diagnosis of MDS is primarily based on the presence of dysplasia in PB and BM cells.

Blasts

The threshold of blasts, the 2% cut-off, which was introduced by the International Prognostic Score System-Rivisited (IPSS-R)⁷, is difficult to interpret because the distinction between blasts categories 0-2% vs > 2 % vs < 5% is not easily reproducible. For this reason, to report the exact number of blasts morphologically detected is recommended, rather than “blasts < 5%”.

Blasts < 20% and AML Diagnosis

With the percentage of blasts < 20%, cytogenetic investigation for abnormal karyotype detection and/or genetic investigation for somatic mutations are crucial for the presence of t(8;21)(q22;q22), inv(16)(p13.1;q22) or (16;16)(p13.1;q22), and RUNX1-RUNX1T1 mutation.

CBFB-MYH11 or PML-RARA detection is already a diagnostic condition for AML, regardless of the blasts percentage.

The detection of other genetic abnormalities, such as t(9;11)(p21.3;q23.3) KMT2AMLLT3, t(6;9)(p23;q34.1) DEK-NUP214 and NPM1 mutations are still controversial.

MDS-Unclassified (MDS-U), 2016 WHO Diagnostic Criteria

MDS-U with single or multiline dysplasia and blasts < 5% into BM, but 1% blasts into PB, the WHO recommends the blasts detection in PB at least in two separate investigations.

In MDS with unilinear dysplasia but pancytopenia, the Hb, ANC and PLT values must be lower than the reference values indicated by IPSS.

Acute erythroid leukemia (AEL) (type erythroid/myeloid), 2016 WHO classification

The myeloid malignancy with erythroid precursors ≥ 50% within nucleated cells in BM and myeloblasts percentage in BM (or PB) < 20%, but ≥ 20% compared to non-erythroid cells, was classified as AEL (erythroid/myeloid subtype)-AML-not otherwise specified (AML-NOS). The 2016 WHO classification identifies these cases as MDS-EB, as it is shown that acute erythroleukemia patients have similar risk-adjusted outcome to RAEB patients, and they do not seem to gain survival advantage with acute myeloid leukemia-type induction chemotherapy.⁸ Pure erythroid leukemia remains as a subtype of AML-NOS.

Immunophenotyping in MDS

Although the flow cytometry immunophenotype (FCI) analysis is an accurate method for qualitative and quantitative evaluation of hematopoietic cells, it alone does not allow the diagnosis of MDS.

Table 5 : Main somatic mutations and more frequent alterations

Mutation	Associated alterations
N-RAS/K-RAS	Associated with thrombocytopenia, blast excess, monocytosis, is most common in CMML
RUNX1	Associated with thrombocytopenia and excess blasts
ASXL1	Is a frequent molecular aberrations in MDS and predict an adverse prognostic outcome
EZH2	Very common in CMML
TP53	Associated with complex and monosomal karyotype, excess blasts, thrombocytopenia, few mutation in other genes
ETV6	Is a common additional abnormality in patients with myelodysplastic syndromes or acute myeloid leukemia and monosomy 7
DNMT3A	Occur early in the course of MDS
U2AF1	Contribute to pathogenesis by causing quantitative changes in splicing

Since in MDS the hematopoietic cells immunophenotype is characterized by the abnormal expression of different cell antigens, FCI analysis must be reproducible between different operators and the result comprehensible for the clinicians.⁹ In addition, the limited availability of markers for the erythroid line, does not always make the evaluation of erythroid line dysplasia easy.¹⁰

FCI can be considered “supportive” for diagnosing MDS and the results must always be integrated with the BM report morphology. When morphology and, mainly, cytogenetics are cogent, an abnormal FCI can be helpful to diagnose MDS.

In Table 4 the main monoclonal antibodies employed about the hematopoietic dysplastic lines study are summarized.

Genetics in MDS

Predicting prognosis is important for defining the risk and treatment options. Abnormalities of karyotype, considered in the current MDS prognostic score, are present in less than 50% of cases. In contrast, somatic mutations associated with the disease have been shown to be much more adherent to support their employment as a prognostic biomarker. Mutations of N-RAS/K-RAS, RUNX1, ASXL1, EZH2, TP53, ETV6, DNMT3A, U2AF1, identify patients with poor prognosis, compared to their non-mutated counterparts (Table 5). Like the karyotype, patients with multiple mutations show

advanced disease, high mortality risk, and AML transformation.¹¹

In MDS-RSSLD and MDS-RSLD, whose diagnoses are made on the presence of ring sideroblasts percentages $\geq 15\%$ or $\geq 5\%$ in presence of SF3B1 mutation respectively, the SF3B1 gene spliceosome mutation is present in more than 70% of cases. In the presence of blasts, the diagnosis of MDS-RSSLD is excluded. If multilineage dysplasia without a blast cell increase is present, a case is classified as MDS-RSMLD.

MDS with isolated del(5q)

For the purposes of diagnosis, del(5q) is the only cytogenetic abnormality that must be present; except for monosomy 7, the 2016 WHO classification does not allow other cytogenetic alterations.

In MDS with isolated del(5q), which generally has a favorable prognosis, the TP53 mutation evaluation and/or p53 detection by immunohistochemistry is recommended.¹² In about 20% of patients with del(5q) and early disease stage, the mutation is present. It identifies a subgroup with adverse prognosis for increased risk of evolution in AML and resistance to lenalidomide therapy.¹³

Blurred categories of MDS, Myeloproliferative Neoplasm and/or Acute Leukemia

These are conditions in which clinical and/or diagnostic aspects can show a blurred diagnostic frame-

work, such as the prevalence of cytopenia, in one or more cell lines, respect to dysplasia, or absence of karyotype abnormalities but presence of somatic specific mutations for hematological pathology but without signs of illness.

Idiopathic Cytopenias of Undetermined Significance (ICUS): cytopenia should be persistent in one or more lines for at least six months, with no other pathologies justifying it, and no other diagnostic criteria that meet MDS diagnosis according to WHO.¹⁴ Some patients show long-lasting cytopenia stability without complications, other patients may have an alternative diagnosis, or evolve towards an open MDS or AML.¹⁵ Patient observation is recommended.

Clonal Cytopenia of Undetermined Significance (CCUS): in cytopenic patients CCUS is a more frequent diagnosis than MDS. In these patients the clonality can explain cytopenia, but the number of mutations, as well as the type, do not seem to have a clear significance prognostic yet. Clinical recognition of CCUS will define it as a formally defined diagnostic entity.¹⁶

Clonal Hematopoiesis of Indetermined Potential (CHIP): generally present in apparently healthy elderly patients, it is characterized by the presence of clonal mutations identical to those found in MDS, and the evolution is towards an open MDS.

Thirty-five percent of ICUS carry MDS-associated somatic mutations and these patients can be identified as CCUS. CCUS and MDS patients who share similar mutations may have diagnostic relevance.¹⁷ However, the presence of isolated MDS somatic mutations associated with unexplained cytopenia is not considered diagnostic for MDS.

Reactive Cytopenia and Dysplasia

It is known that some conditions, such as vitamin B₁₂ and/or folate deficiency, HIV infection, copper deficiency¹⁸, alcohol abuse, and drugs (e.g. methotrexate) can cause cytopenia and dysplasia. In addition, it should be stressed that in some ethnic groups, the neutrophils absolute reference value is lower than Caucasian, as well as the platelets value.¹⁹ Then, in these cases the isolated neutropenia should be well interpreted.

In some normal subjects, dysplasia can be more than 10%, but it is generally limited to a single cell line and without preponderant morphological aspects. Moreover, the presence of cytopenia is not due to neoplastic conditions.

In the elderly, TET2 mutations can be detected with acquired clonal hematopoiesis. In addition to TET2 mutation, DNMT3A, ASXL1 and SF3B1 mutations may represent a pre-malignant conditions that cause a clonal hematopoietic expansion.

Discussion and Conclusion

In oncohematology, morphology still plays an important role as a “first engine”, mainly in these hematologic neoplasms in which the detection of typical morphological aspects, as well as the accurate counting of blasts are crucial for starting further investigation and which have a significant impact on overall patient management.

The fundamental contribution of genetic mutations, in addition to cytogenetics for a MDS diagnosis, allows us to define the prognosis and, consequently, to select patients for a more appropriate therapy. Moreover, family germ line mutations have allowed us to identify patients subgroups in which family study is justified for certain categories of genes (e.g. CEPBA, DDX41, RUNX1, ANKRD26, ETV6, GATA2)²⁰.

REFERENCES

1. Scheinberg P, DeZern AE, Steensma DP. Acquired marrow failure syndromes: aplastic anemia, PNH and MDS. American Society of Hematology Self-Assessment Program Textbook 2016: 478-520.
2. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. *Blood* 89: 2079-2088, 1997.
3. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 127: 2391-2405, 2016.
5. Invernizzi R, Quaglia F, Della Porta MG. Importance of classical morphology in the diagnosis of myelodysplastic syndrome. *Mediterr J Hematol Infect Dis* 7: e2015035, 2015.

6. Goasguen JE, Bennett J, Bain BJ, et al. Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. International Working Group on Morphology of MDS IWGM-MDS. *Leuk Res* 45: 75-81, 2016.
7. Greenberg PL, Tuechler H, Schanz J et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. *Blood* 120: 2454-2465, 2012.
8. Wang SA, Patel KP, Pozdnyakova O, et al. Acute erythroid leukemia with < 20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. *Modern Pathology* 29: 1221-1231, 2016.
9. Della Porta M.G., Picone C. Diagnostic utility of flow cytometry in myelodysplastic syndromes.. *Mediterr J Hematol Infect Dis* 9: e2017017, 2017.
10. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. *Leukemia* 20: 549-555, 2006.
11. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 122: 3616-3627, 2013.
12. McGraw KL, Johnny Nguyen J, Komrokji RS, et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. *Haematologica* 101: e320–e323, 2016.
13. Pellagatti A, Boultonwood J. The molecular pathogenesis of the myelodysplastic syndromes. *Eur J Haematol* 95: 3-15, 2015.
14. Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). *Hematology* 2015: 299-307, 2015.
15. Scheinberg P, DeZern AE, Steensma DP. Acquired marrow failure syndromes: aplastic anemia, PNH and MDS. *American Society of Hematology Self-Assessment Program textbook*. 2016: 478-520.
16. Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. *Blood* 126: 2355-2361, 2015.
17. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* 126: 9-16, 2015.
18. D'Angelo G. Copper deficiency mimicking myelodysplastic syndrome. *Blood Res* 51: 217-219, 2016.
19. D'Angelo G. Ethnic and genetic causes of neutropenia: clinical and therapeutic implications. *Laboratory Hematology* 15: 25-29, 2009.
20. West AH, Godley LA, Chumpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. *Ann N Y Acad Sci* 1310: 111-118, 2014.

Correspondence:

Guido D'ANGELO, M.D.
 Hematology/Coagulation
 Laboratory of Clinical-Chemistry, Hematology and
 Microbiology
 ASST- Gallarate Hospital
 Varese / ITALY

Tel. +39 0331. 751456
 Fax +39 0331. 751789
 e-mail: danguido@libero.it